{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:23Z","timestamp":1790409263205,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Belantamab mafodotin (belamaf)\u2010containing regimens are effective treatment options for patients with relapsed and\/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed by physicians, following appropriate training, to minimize their impact on the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop clinical recommendations for the identification, monitoring, and management of ocular events associated with belamaf therapy, and guidance for any required dose modification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>A systematic literature review was conducted and an international group of hematologists and ophthalmologists reviewed clinical trial data, real\u2010world evidence, and published literature on belamaf\u2010associated ocular events. This literature review and the collective experience and expertise of the panel of experts informed the recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Belamaf\u2010associated ocular events are common side effects of treatment, which are managed primarily with appropriate dose modification and decreased frequency of dosing, as well as the use of artificial tears. These events affect the corneal epithelium, are mainly Grade 1 and 2 per the Keratopathy and Visual Acuity scale and are reversible in almost all patients. In general, before initiating belamaf therapy, all patients should undergo a baseline ophthalmic evaluation with an eye specialist. However, if there are delays in obtaining ophthalmic evaluation, or if a patient is rapidly progressing, treatment should be initiated, and ophthalmic evaluation should be undertaken as soon as possible. Patients should be also evaluated by an eye specialist before administering the next three belamaf doses (i.e., before Cycles 2, 3, and 4); dose modifications, as described in this paper, may apply if required. Importantly, modifying the belamaf dose in response to an ocular event is not associated with any reductions in treatment efficacy. After Cycle 4, the treating physician may use the Vision\u2010Related Anamnestic tool, alongside clinical judgment, to decide whether to administer the next dose of belamaf or to refer the patient to an eye specialist (i.e., if the patient experiences new worsening of vision or if the ocular events have neither improved after 8\u2009weeks nor resolved after 12\u2009weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The expert panel developed recommendations for managing belamaf\u2010associated ocular events, with the aim of contributing to the ease of clinical use of belamaf and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ajh.70015","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:50:10Z","timestamp":1753692610000},"page":"1839-1850","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Practical Guidance on Clinical Management of Belantamab Mafodotin\u2010Associated Ocular Events"],"prefix":"10.1002","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Institute of Cancer Molecular and Cellular Biology University Hospital of Salamanca\/Institute of Biomedical Research of Salamanca, Salamanca University  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Alejandre","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Colby","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology New York University Grossman School of Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens  Athens Greece"},{"name":"Department of Medicine Korea University  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Degli","family":"Esposti","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim V.","family":"Farooq","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science University of Chicago Medical Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Turin, Azienda Ospedaliero\u2010Universitaria Citt\u00e0 Della Salute e Della Scienza di Torino  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Cl\u00ednica S\u00e3o Germano  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2 University Hospital of W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Service D'h\u00e9matologie et Th\u00e9rapie Cellulaire H\u00f4pital La Mil\u00e9trie, and Centre D'investigation Clinique INSERM 1402, Poitiers University Hospital  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"St. Vincent's Hospital Melbourne University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (PUMC)  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Oxford Translational Myeloma Centre, NDORMS University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancies, Department of Medical Oncology Dana\u2010Farber Cancer Institute, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001135\u20102"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010024\u201000529\u20107"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","unstructured":"A.Loubert L.Bunod M.M'Hari F.Pompilus M.Purser andS.McNamara \u201cThe Impact of Patient\u2010Reported Adverse Events on Quality of Life: An Analysis of the DREAMM\u20107 and DREAMM\u20108 Randomized Controlled Trials \u201d Poster presented at: 66th ASH Annual Meeting and Exposition; December 7\u201310 2024; San Diego CA USA.","DOI":"10.1182\/blood-2024-200299"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00243\u20100"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.4.4"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285205"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000494\u20104"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123\u2010020\u201000280\u20108"},{"key":"e_1_2_13_13_1","unstructured":"E.Terpos M.Gavriatopoulou I.Ntanasis\u2010Stathopoulos et\u00a0al. \u201cEvaluation of a Novel Method Guiding Belantamab Mafodotin Dosing in Multiple Myeloma Based on a Patient\u2010Reported Questionnaire \u201d Poster presented at: 2024 ASCO Annual Meeting; May 31\u2013June 4 2024; Chicago IL USA."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1138453"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.2.219"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433\u2010020\u20100806\u20103"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27133"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27219"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284347"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487\u2010022\u201000212\u20105"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","unstructured":"M. V.Mateos S.Trudel H.Quach et\u00a0al. \u201cModification of Belantamab Mafodotin Dosing Schedule to Balance Efficacy and Tolerability: Experience From the Phase 3 DREAMM\u20107 and DREAMM\u20108 Studies. Manuscript Under Review \u201d2025.","DOI":"10.1182\/bloodadvances.2025016949"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","unstructured":"E.Terpos M.Gavriatopoulou I.Ntanasis\u2010Stathopoulos et\u00a0al. \u201cBelantamab Mafodotin Plus Lenalidomide\/Dexamethasone in Newly Diagnosed Intermediate\u2010Fit and Frail Multiple Myeloma Patients: Long\u2010Term Efficacy and Safety From the Phase 1\/2 BelaRd Clinical Trial \u201d Poster presented at: 2025 ASCO Annual Meeting; May 30\u2013June 3 2025; Chicago IL USA.","DOI":"10.1200\/JCO.2025.43.16_suppl.7512"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","unstructured":"S.Trudel M.Beksac L.Pour et\u00a0al. \u201cResults From the Randomized Phase 3 DREAMM\u20108 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma \u201d Presented at: 2024 ASCO Annual Meeting; May 31\u2013June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA105"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","unstructured":"V.Hungria P.Robak M.Hus et\u00a0al. \u201cCharacterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Bortezomib and Dexamethasone in the DREAMM\u20107 Study \u201d Poster presented at: 21st IMS Annual Meeting; September 25\u201328 2024; Rio de Janeiro Brazil.","DOI":"10.1016\/S2152-2650(24)02298-5"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152\u20102650(24)02315\u20102"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1274659"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_13_28_1","unstructured":"E.Terpos M.Gavriatopoulou andI.Ntanasis\u2010Stathopoulos \u201cLess Is More: Deciphering the Association Between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma Poster presented at: 66th ASH Annual Meeting and Exposition; December 7\u201310 2024; San Diego CA USA."},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010209915"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.08.003"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","unstructured":"M. V.Mateos P.Robak M.Hus et\u00a0al. \u201cResults From the Randomized Phase 3 DREAMM\u20107 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Bortezomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma \u201d Presented at: 2024 ASCO Annual Meeting; May 31\u2013June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.36_suppl.439572"},{"key":"e_1_2_13_32_1","unstructured":"GlaxoSmithKline UK Limited \u201cBLENREP (Belantamab Mafodotin). Summary of Product Characteristics \u201d2025 https:\/\/www.medicines.org.uk\/emc\/product\/100782\/smpc."},{"key":"e_1_2_13_33_1","volume-title":"StatPearls","author":"Lee S. Y.","year":"2025"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002703\u2010y"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7543"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1429"},{"issue":"1","key":"e_1_2_13_37_1","first-page":"38","article-title":"Doctor\u2010Patient Communication: A Review","volume":"10","author":"Ha J. F.","year":"2010","journal-title":"Ochsner Journal"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010018\u20100141\u20100"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000369\u20100"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1729734"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T06:59:53Z","timestamp":1766386793000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/ajh.70015"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70015","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"2025-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}